AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:05 2024-05-30 am EDT 5-day change 1st Jan Change
12,028 GBX +0.82% Intraday chart for AstraZeneca PLC -3.03% +13.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Goldman Sachs Starts AstraZeneca With Buy Rating, $97 Price Target MT
Goldman Sachs Kicks Off AstraZeneca Coverage at Buy MT
Jefferies and UBS cut Anglo American AN
Dr Martens cuts payout as profit plummets AN
ASTRAZENECA : Is no more a Sell but a Buy opportunity for Goldman Sachs ZD
Fusion Pharmaceuticals Shareholders Approve AstraZeneca Deal MT
AstraZeneca drug lowers cholesterol in phase 1 trial AN
Cellectis: operations financed until 2026 CF
Astrazeneca Says AZD0780 Demonstrated Significant LDL-C Reduction On Top Of Statin In Phase I Trial RE
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval DJ
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
AstraZeneca Says Potential Lung Cancer Treatment Improved Overall Survival Compared With Chemotherapy MT
ASTRAZENECA : JP Morgan reiterates its Buy rating ZD
AstraZeneca: positive trial in lung cancer CF
Astrazeneca Pharma India's Net Profit Rises in Fiscal Q4 MT
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial MT
Monetary policy still drives investor sentiment Our Logo
AstraZeneca: favorable results in bronchial cancer CF
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival MT
Astra, Daiichi hail positive survival data for Dato-DXd AN
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial CI
Innate Pharma: five abstracts selected for ASCO CF
Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
151.7 USD
Average target price
172 USD
Spread / Average Target
+13.40%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT